Inclusion Criteria:
  -  Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
  -  For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.
Exclusion Criteria:
  -  For on-treatment participants: a positive serum pregnancy test.
  -  For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
  -  Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.